We are excited to announce that Osteosarcoma Now and ONTEX has transitioned to ownership under The Bardo Foundation. This change represents a significant opportunity for advancement, while preserving the mission and core values that unite our community.

We extend sincere appreciation to the Myrovlytis Trust and the dedicated team responsible for establishing and managing Osteosarcoma Now. Their vision and commitment have positively impacted countless individuals affected by osteosarcoma, and we are privileged to further this important legacy.

As we assume stewardship, our priorities will remain centred on serving the osteosarcoma community with integrity, transparency, and meaningful impact. In the coming months, our goals include:

Continue to fund and advance osteosarcoma research through The Bardo Foundation

Enhance resources designed to better support our community

Develop and improve ONTEX using the latest AI technology to speed up the process of reporting clinical trials

Ongoing communication through the Osteosarcoma Now newsletter

Above all, Osteosarcoma Now will continue to be a supportive environment where compassion, information, and progress converge to improve lives. We value your engagement in this community and welcome your partnership as we look toward continued growth.

Thank you for your trust and support as we embark on this new chapter together.

To receive updates about Osteosarcoma Now and access our specialised clinical trial database, please subscribe to our newsletter by clicking here.